DISP-12. BRAIN CANCER CANADA FUNDS CRITICALLY NEEDED RESEARCH AND ADVOCATES FOR PATIENTS, WITH THE AIM TO IMPROVE OUTCOMES FOR CANADIANS DIAGNOSED WITH PRIMARY MALIGNANT BRAIN TUMOURS
Bibliographic record
Abstract
Abstract Brain Cancer Canada (BCC) is a national, volunteer-driven charity supporting paediatric and adult primary malignant brain tumour research and patient advocacy. To achieve these goals BCC 1) awards grants to Canadian doctors and scientists advancing brain cancer research, and 2) advocates for equitable pharmacare for brain cancer patients. BCC is committed to funding innovative research projects, with the aim to improve treatment options for patients. Led by its Scientific Advisory Committee, submissions are reviewed, screened, and undergo a systematic evaluation by the panel. Recommendations on successful proposals are provided to the board for approval. This May, the charity awarded 5 research grants, totaling $380,000 CAD. These projects include supporting the acquisition of a next-generation DNA Sequencer, advancing FET-PET/MRI imaging, pioneering a novel approach to combat Diffuse Intrinsic Pontine Glioma (DIPG), developing a novel dual-hit therapeutic approach for glioblastoma, and other projects focusing on precision medicine. BCC has taken a deliberate and firm stand in highlighting the drug coverage disparities that exist for patients afflicted with brain cancer BCC’s Pharmacare Advocacy Committee has found that disparities exist owing to the lack of a national drug program, and a patchwork of alternative schemes varying by province/territory. These findings are well documented by others. For example, our research shows that temozolomide (TMZ), the global standard of care for treating gliomas, is not covered in 4 provinces. Our pharmacare research on TMZ and 5 other drugs further confirm the disparity in coverage that hinders patient welfare and imposes a confusing and detrimental strain on the healthcare system. With, the dependence on take-home medication increasing, it is critical we take immediate action in supporting this marginalized group. With the support of The Society for Neuro-Oncology, Brain Cancer Canada will be better positioned to reach its goals and support people affected by primary malignant brain tumours.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.010 | 0.030 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.002 | 0.002 |
| Science and technology studies | 0.008 | 0.002 |
| Scholarly communication | 0.009 | 0.002 |
| Open science | 0.002 | 0.005 |
| Research integrity | 0.004 | 0.004 |
| Insufficient payload (model declined to judge) | 0.222 | 0.044 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".